Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) CFO Richard Bryan Riggsbee sold 9,400 shares of the firm’s stock in a transaction that occurred on Friday, January 20th. The stock was sold at an average price of $20.04, for a total transaction of $188,376.00. Following the completion of the transaction, the chief financial officer now directly owns 364,107 shares in the company, valued at $7,296,704.28. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Richard Bryan Riggsbee also recently made the following trade(s):
- On Wednesday, January 18th, Richard Bryan Riggsbee sold 600 shares of Myriad Genetics stock. The stock was sold at an average price of $20.01, for a total transaction of $12,006.00.
- On Tuesday, December 27th, Richard Bryan Riggsbee sold 20,000 shares of Myriad Genetics stock. The stock was sold at an average price of $15.15, for a total transaction of $303,000.00.
Myriad Genetics Stock Up 5.2 %
Shares of NASDAQ MYGN opened at $21.41 on Tuesday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -22.07 and a beta of 1.75. Myriad Genetics, Inc. has a 52-week low of $13.92 and a 52-week high of $28.18. The business’s 50 day moving average is $18.04 and its two-hundred day moving average is $20.49.
Hedge Funds Weigh In On Myriad Genetics
Large investors have recently bought and sold shares of the stock. Comerica Bank boosted its stake in Myriad Genetics by 2.4% in the second quarter. Comerica Bank now owns 108,409 shares of the company’s stock valued at $2,466,000 after acquiring an additional 2,590 shares in the last quarter. Strs Ohio boosted its stake in Myriad Genetics by 9.5% in the second quarter. Strs Ohio now owns 48,400 shares of the company’s stock valued at $879,000 after acquiring an additional 4,200 shares in the last quarter. Walker Asset Management LLC purchased a new stake in shares of Myriad Genetics in the second quarter valued at about $412,000. Sei Investments Co. raised its holdings in shares of Myriad Genetics by 32.7% in the second quarter. Sei Investments Co. now owns 1,178,664 shares of the company’s stock valued at $21,416,000 after buying an additional 290,269 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its holdings in shares of Myriad Genetics by 2.0% in the second quarter. Maryland State Retirement & Pension System now owns 32,660 shares of the company’s stock valued at $593,000 after buying an additional 638 shares during the last quarter. Institutional investors and hedge funds own 99.08% of the company’s stock.
Wall Street Analysts Forecast Growth
MYGN has been the topic of several analyst reports. Stephens initiated coverage on shares of Myriad Genetics in a research report on Wednesday, October 5th. They set an “equal weight” rating and a $22.00 price target on the stock. Raymond James raised shares of Myriad Genetics from a “market perform” rating to an “outperform” rating and set a $25.00 price target on the stock in a research report on Wednesday, January 18th. StockNews.com initiated coverage on shares of Myriad Genetics in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, SVB Leerink reduced their price target on shares of Myriad Genetics from $27.00 to $25.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $25.40.
About Myriad Genetics
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.